ALTHE.PA Theraclion SA

Healthcare Health Care Equipment & Supplies Euronext Paris
0.7010 EUR
Close of Nov 8, 2026
0.4020 0.9300
Market cap
EUR 51.7M
P/E
-
P/B
3.21x
ROE
-
Dividend yield
-
Fundamental score
1.0/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is ALTHE.PA undervalued?

Graham number

The Graham number of Theraclion SA cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Theraclion SA fundamental analysis

2 of 11 checks passed

ROE 2/2

The stock's ROE exceeds expectations (1593.22%), revealing strong profitability and efficient use of shareholders' equity, making it an attractive investment opportunity.

ROA 0/2

The stock's ROA (-45.85%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

PBV 0/2

The stock's elevated P/BV ratio (26.97x) raises concerns about its overvaluation, making it an imprudent choice for investors seeking value.

DER 0/2

The company has a high debt to equity ratio (461%), which means it owes a lot of money compared to what it actually owns, making it financially risky.

Revenue Growth 0/2

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

Net Profit Growth 0/2

Over the past five years, this company's net profit has failed to exhibit any growth, indicating a stagnant financial performance and making it a less favorable choice for potential investors.

Assets Growth 2/2

With continuous growth in revenue over the last five years, this company has proven to be a lucrative investment option, showcasing its strong financial performance.

Graham Number 0/1

Based on the Graham number, this company's stock price appears to be higher than its intrinsic value, signaling a potentially unfavorable investment choice.

Dividend Growth 0/2

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

Dividend 0/2

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

Buffet Intrinsic Value 0/1

Warren Buffett's formula suggests that the company's stock is overpriced (0), presenting a possible disadvantage for investors as its market price surpasses its estimated intrinsic value.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Theraclion SA stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Theraclion SA

Theraclion SA provides therapeutic ultrasound technology for seamless vein care. It offers SONOVEIN, a robotic solution for the non-invasive echotherapy treatment of varicose veins; ECHOPULSE, a robotic and non-invasive solution for the echotherapy treatment of thyroid nodules and breast fibroadenoma; and EPack, a disposable that is installed on the device before treatment to protect the patient's skin and optimize image quality. The company was incorporated in 2004 and is h…

Full company profile